Entry |
|
Name |
Vonicog alfa (USAN); Vonicog alfa (genetical recombination) (JAN); Von willebrand factor; Wilfactin (TN); Vonvendi (TN) |
Formula |
C9712H15373N2737O3032S210
|
Exact mass |
225574.4238
|
Mol weight |
225723.1487
|
Class |
Cardiovascular agent
DG02016 Hemostatics
DG02013 Blood coagulation factor
DG02014 Blood coagulation accelerant
DG02013 Blood coagulation factor
|
Remark |
Therapeutic category: | 6349 |
|
Efficacy |
Anticoagulant, Hemostatic, Replenisher (von Willebrand factor) |
Comment |
recombinant von Willebrand factor (vWF) [HSA: 7450] [KO: K03900]
Prophylactic treatment of bleeding episodes and Von Willebrand disease
|
Interaction |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B02 ANTIHEMORRHAGICS
B02B VITAMIN K AND OTHER HEMOSTATICS
B02BD Blood coagulation factors
B02BD10 von Willebrand factor
D08681 Vonicog alfa (USAN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
63 Biological preparations
634 Human blood preparations
6349 Others
D08681 Vonicog alfa (USAN); Vonicog alfa (genetical recombination) (JAN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D08681
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D08681
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D08681
|
Other DBs |
|
LinkDB |
|